Page 4 - Revised January News Today : Breaking News, Live Updates & Top Stories | Vimarsana

National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia

/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that REZLIDHIA™ (olutasidenib) has been added by the National Comprehensive Cancer.

United statesSouth san franciscoDavid rosenRaul rodriguezRigel pharmaceuticals incDrug administrationPrnewswire rigel pharmaceuticals incExchange commissionEuropean medicines agencyNational comprehensive cancer networkAmerican cancer societyNational comprehensive cancerPractice guidelinesFull prescribing informationRigel pharmaceuticalsAmerican cancer

Rigel Pharmaceuticals Provides Business Update

/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update including preliminary total revenue for the fourth quarter, ongoing.

United statesSouth san franciscoDavid rosenRaul rodriguezEli lillyRigel pharmaceuticals incDrug administrationExchange commissionPrnewswire rigel pharmaceuticals incKissei pharmaceutical co ltdKissei upon japan pharmaceuticalsEuropean medicines agencyDevices agencyAmerican cancer societyPreliminary financialMedical devices agency

Rigel Pharmaceuticals Provides Business Update

Rigel Pharmaceuticals Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSouth san franciscoRaul rodriguezEli lillyRigel pharmaceuticals incDrug administrationExchange commissionPrnewswire rigel pharmaceuticals incRigelrigel pharmaceuticals incKissei pharmaceutical co ltdKissei upon japan pharmaceuticalsEuropean medicines agencyDevices agencyAmerican cancer societyPreliminary financialMedical devices agency

Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U S for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that REZLIDHIA™ (olutasidenib) capsules are available in the U.S. by prescription.

United statesSouth san franciscoDavid rosenRaul rodriguezRigel pharmaceuticals incForma therapeutics incDrug administrationPrnewswire rigel pharmaceuticals incExchange commissionEuropean medicines agencyAmerican cancer societyNurse navigatorForma therapeuticsFull prescribing informationRigel pharmaceuticalsAmerican cancer

Rigel Announces U S FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Announces U S FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSouth san franciscoCecilf whitaker jrDavid rosenPrecautionsdifferentiation syndromeRigel contactsmediaRaul rodriguezJorgee cortesRigel pharmaceuticals incForma therapeutics incDrug administrationExchange commissionPrnewswire rigel pharmaceuticals incRigelrigel pharmaceuticals incGeorgia cancer centerEuropean medicines agency